文献速递妇科产科

基于人群的卵巢、输卵管、腹膜或未指定原发部位浆液性癌女性生存研究——代表瑞典妇科癌症组(SweGCG)

Population-based study of survival for women with serous cancer of the ovary, fallopian tube, peritoneum or undesignated origin - on behalf of the Swedish gynecological cancer group (SweGCG).
PubMed 文献 · Gynecol Oncol · 2016-11-03

瑞典全国性基于人群研究纳入2009-2013年诊断的非子宫浆液性癌女性,共2359例浆液性癌,5年相对生存率总体37%,输卵管癌54%、卵巢癌40%、腹膜癌34%、未指定原发部位13%;在多变量分析中,原发部位与生存无独立关联,而未指定原发部位癌生存更差。

要点

  • 浆液性癌中71%原发卵巢、9%输卵管、9%腹膜、11%未指定原发部位。
  • 5年相对生存率:输卵管癌54%、卵巢癌40%、腹膜癌34%、未指定原发部位13%。
  • 在多变量分析中,原发部位与生存无独立关联;晚期、低分化、新辅助化疗、残留肿瘤和铂单药与更差生存相关。

核心结论

  • 未指定原发部位的浆液性癌生存比卵巢、输卵管和腹膜浆液性癌更差;在报告和比较卵巢癌生存率时需关注未指定原发部位的浆液性癌。

研究设计与样本

  • 瑞典全国性基于人群研究,纳入2009-2013年诊断为组织学证实的非子宫浆液性癌、年龄≥18岁、录入瑞典卵巢输卵管腹膜原发癌质量登记的女性。
  • 共识别5627例女性,其中1246例(22%)为交界性肿瘤,4381例为恶性肿瘤;共2359例浆液性癌。
  • 使用Ederer II法估计相对生存率,采用泊松回归模型进行简单和多变量分析。

主要发现

  • 2359例浆液性癌中,71%原发卵巢(OC),9%原发输卵管(FTC),9%原发腹膜(PPC),11%原发部位未指定(UPS)。
  • 估计5年相对生存率总体为37%;FTC为54%,OC为40%,PPC为34%,UPS为13%。
  • 在限于接受初次或间歇性减瘤手术的OC、FTC和PPC女性的多变量回归分析中,原发部位与生存无独立关联。
  • 与更差生存显著相关的因素包括:晚期(RR 2.63,P<0.001)、中分化(RR 1.90,P<0.047)和低分化(RR 2.20,P<0.009)、新辅助化疗(RR 1.33,P<0.022)、残留肿瘤(RR 2.65,P<0.001)以及铂单药对比铂联合化疗(RR 2.34,P<0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of the study was to determine survival outcome in patients with serous cancer in the ovary, fallopian tube, peritoneum and of undesignated origin. METHODS: Nation-wide population-based study of women≥18years with histologically verified non-uterine serous cancer, included in the Swedish Quality Registry for primary cancer of the ovary, fallopian tube and peritoneum diagnosed 2009-2013. Relative survival (RS) was estimated using the Ederer II method. Simple and multivariable analyses were estimated by Poisson regression models. RESULTS: Of 5627 women identified, 1246 (22%) had borderline tumors and 4381 had malignant tumors. In total, 2359 women had serous cancer; 71% originated in the ovary (OC), 9% in the fallopian tube (FTC), 9% in the peritoneum (PPC) and 11% at an undesignated primary site (UPS). Estimated RS at 5-years was 37%; for FTC 54%, 40% for OC, 34% for PPC and 13% for UPS. In multivariable regression analyses restricted to women who had undergone primary or interval debulking surgery for OC, FTC and PPC, site of origin was not independently associated with survival. Significant associations with worse survival were found for advanced stages (RR 2.63, P<0.001), moderate (RR 1.90, P<0.047) and poor differentiation (RR 2.20, P<0.009), neoadjuvant chemotherapy (RR1.33, P<0.022), residual tumor (RR 2.65, P<0.001) and platinum single (2.34, P<0.001) compared to platinum combination chemotherapy. CONCLUSION: Survival was poorer for serous cancer at UPS than for ovarian, fallopian tube and peritoneal cancer. Serous cancer at UPS needs to be addressed when reporting and comparing survival rates of ovarian cancer.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Dahm-Kähler P, Borgfeldt C, Holmberg E, et al. Population-based study of survival for women with serous cancer of the ovary, fallopian tube, peritoneum or undesignated origin - on behalf of the Swedish gynecological cancer group (SweGCG). Gynecol Oncol. 2016. PMID: 27817932. doi:10.1016/j.ygyno.2016.10.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。